Results 221 to 230 of about 216,038 (323)

A Bibliometric Analysis of Testosterone Replacement Therapy Studies: Mapping the Scientific Landscape. [PDF]

Med J Islam Repub Iran
Faryabi A, Aazami H, Norouzi F, Fattahi MR, Dehghanbanadaki H.   +4 more
europepmc   +1 more source

Prostate zonal impact of 5α‐reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer

BJU International, Volume 137, Issue 2, Page 332-338, February 2026.
Objectives To assess the impact of 5α‐reductase inhibitors (5‐ARIs) on multiparametric magnetic resonance imaging (mpMRI) features of Prostate Imaging‐Reporting and Data System (PI‐RADS) lesions and their influence on the detection of clinically significant prostate cancer (csPCa), with a focus on differences between prostate zones.
Arighno Das, Marcelo Bigarella, Krista Brackman, Glenn O. Allen, Soroush Rais‐Bahrami, Kayla Bahr, Emily Schmitt, Andrew M. Fang, Hunter Boudreau, Christopher P. Filson, Melina Pectasides, Giuseppe V. Toia, David F. Jarrard   +12 more
wiley   +1 more source

Vitamin D Status Determines Cardiometabolic Effects of Testosterone Replacement Therapy in Men with Late-Onset Hypogonadism. [PDF]

Nutrients
Krysiak R, Kowalcze K, Szkróbka W, Okopień B.   +3 more
europepmc   +1 more source

ACTH-producing pituitary adenomas in Cushing´s disease [PDF]

, 1980
Fahlbusch, R., Müller, O. A., Scriba, Peter Christian, Stass, P.   +3 more
core  

Puberty‐Promoting Treatment and Psychosocial Well‐Being in Boys With Constitutional Delay of Puberty: A Randomized Controlled Trial

Clinical Endocrinology, Volume 104, Issue 2, Page 139-146, February 2026.
ABSTRACT Objective In boys, constitutional delay of growth and puberty (CDGP) has been associated with diverse negative psychosocial effects. Albeit alleviating distress is one of the main reasons for inducing pubertal development, the impact of puberty‐promoting treatment on psychosocial wellbeing is under‐researched.
Laura Kariola, Tero Varimo, Mitja Lääperi, Hanna Huopio, Sirpa Tenhola, Raimo Voutilainen, Jorma Toppari, Silja Kosola, Päivi J. Miettinen, Olli Raitakari, Marko Elovainio, Taneli Raivio, Matti Hero   +12 more
wiley   +1 more source

A Case of Hidradenitis Suppurativa Responsive to Testosterone Replacement Therapy. [PDF]

Indian Dermatol Online J
Stone C, Murrell DF.
europepmc   +1 more source

Mixed Gonadal Dysgenesis: A Comprehensive Review of Clinical Spectrum, Diagnostic Strategies, and Management Approaches

Clinical Endocrinology, Volume 104, Issue 2, Page 92-102, February 2026.
ABSTRACT Background Mixed gonadal dysgenesis (MGD) is a rare form of differences in sex development (DSD) typically associated with 45,X/46,XY mosaicism. The phenotypic presentation of MGD varies from atypical genitalia to typical male or female appearances often associated with Turner stigmata.
Dinesh Giri, Sushil Yewale, Hannah Hickingbotham, Cara Williams, Mohamed Shalaby, Julie Alderson, Julie Park   +6 more
wiley   +1 more source

Effects of Testosterone Replacement Therapy on Metabolic Syndrome in Male Patients-Systematic Review. [PDF]

Int J Mol Sci
Mlynarz N, Miedziaszczyk M, Wieckowska B, Szalek E, Lacka K.   +4 more
europepmc   +1 more source

A Systematic Review Investigating the Psychosocial Factors Influencing Initiation, Use and Subjective Experience of Performance and Image‐Enhancing Drugs in Women Who Weight‐Train

Drug and Alcohol Review, Volume 45, Issue 2, February 2026.
ABSTRACT Issue Performance and image‐enhancing drug (PIED) use among women is a growing phenomenon, particularly within weight‐training populations. Despite increasing prevalence, research on the psychosocial factors involved in women's PIED use remains emergent and fragmented.
Hannah C. Schuurs, Zoe Walter, Leanne Hides, Mair Underwood   +3 more
wiley   +1 more source

Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 803-816, February 2026.
Abstract Treatment with GLP‐1 receptor agonists (GLP‐1 RAs) is effective in reducing body weight in individuals with overweight and type 2 diabetes (T2D). However, measurements indicate that a considerable portion of the weight loss derives from fat‐free mass (FFM), including skeletal muscle, which may compromise metabolic health and physical function.
Viktor Aimelet, Jens Juul Holst
wiley   +1 more source